DHC Group and Otsuka Pharmaceuticals Host September Virtual Summit Series
Brooklyn, NY (September 08, 2021) The DHC Group and Otsuka America Pharmaceutical, Inc. (Otsuka), a global leader in developing solutions for unmet mental health needs, are hosting the September Virtual Summit Series event on September 9th and 10th at 12pm ET. The DCH Group and Otsuka share a commitment to digital medicine to improve patient outcomes and mission to advance digital innovation within the healthcare industry.
The virtual event will aim to kick off the fall planning season by bringing together healthcare marketers, research experts, and change makers to openly discuss current challenges, hear exclusive reports from DHC projects, and trigger new ideas on innovation. Over the course of two days, content will be shared via presenters and panelists in an interactive virtual format, and discussion will center on The Future of Digital Medicine and Addressing Health Access, Inequity, and Inclusion Through Digital Innovation.
Speakers and panelists feature healthcare marketing experts and thought leaders from a diverse range of roles within the healthcare industry to provide a multi-dimensional perspective on the current landscape, solutions to challenges and ideas to innovate. Keynote speaker, Solome Tibebu, is a behavioral health strategist passionate about frontier technologies and solutions transforming mental health, equity and access. Solome’s work has spanned behavioral health and human service consulting, venture capital, corporate development and various operating roles at behavioral health software companies large and small. Additional contributors to the September 10th conversation around health equity and access include Otsuka’s Debbie Profit (VP, Applied Innovation and Process Improvement) and Spencer Curtis (Head of Digital Portfolio Strategy).
The event will kick-off on September 9th (noon eastern) with a robust set of experts on the Future of Digital Medicine. DHC Advisory Board Member and leading subject matter expert Shwen Gwee will set the tone for the day with a look at the state of the industry today. Virtual attendees will hear case studies on the innovative efforts of the Tilak/Novartis partnership, and the industry-leading Otsuka/Click Therapeutics work in digital therapeutics. Rohit Bansal Senior Director, Digital Therapeutics Commercial Lead for Otsuka will join DHC Co-Founder Mark Bard for a fireside chat.
DHC events are supported and attended by corporate members and current employees of pharmaceutical and biotech companies – in line with DHC’s mission to provide insights and strategies to enhance the professional development of marketing executives within the healthcare industry. “DHC events help us grow and learn about and consider new ideas and tools as we look to the future.” said Jay Denhart-Lillard, Genentech.
To view the full agenda or to register visit digitalhealthcoalition.org/september-virtual-summit-series.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology, and cardiology, using cutting-edge technology to address unmet healthcare needs.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13.3 billion in 2020.
All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en.
About the DHC Group and The Digital Health Coalition
Expanding on the legacy of the 501(c)(3) nonprofit organization Digital Health Coalition, the DHC Group funds and conducts research, hosts and produces industry events, while offering media and outreach opportunities for its members. The DHC Group partners with numerous industry outlets, including the Digital Health Coalition, to drive industry thought leadership forward and and make research-supported content available to a broader audience of pharmaceutical, media, publishing, technology, and advertising firms interested in the future of digital health, marketing, and customer experience.
The Digital Health Coalition is a 501(c)(3) nonprofit created to serve as the collective voice and industry rallying point for the discussion of the current and future issues relevant to digital marketing of healthcare products and services. The DHC engages multiple and diverse stakeholders through research, events, and advocacy projects and then recommend specific actions that will drive innovation. The DHC seeks member companies to help improve the use of digital technologies to engage patients and providers, and to advocate for biopharma’s role as a key stakeholder in the healthcare ecosystem.